pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,599 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1894Endpoints1467Fierce Biotech780BioSpace768BioPharma Dive556raps257onclive165fda recalls
therapy area
allOncology13097Rare Disease3407Immunology3069Cardiology2875Hematology2338Pulmonology2300Vaccines
  • FDA releases details on accelerated approval process for personalized gene therapies
    The U.S. Food and Drug Administration has issued additional guidance on a faster approval pathway designed for personalized gene therapies. The new details outline how sponsors can seek expedited r…
    STAT · 26d agoRegulatoryPositive↗ source
  • Artiva Biotherapeutics to cease operations after two deaths in autoimmune cell therapy trials
    Artiva Biotherapeutics announced it will wind down and lay off nearly all staff following two patient fatalities in its autoimmune cell therapy trials. The deaths occurred during clinical testing…
    Endpoints · 26d agoNegative↗ source
← prev
page 19 of 144
next →
126
fda medwatch117
globenewswire health73
fda press62
1892
Psychiatry & CNS1247
Ophthalmology1150
Endocrinology & Metabolism809
Pain801
Nephrology789
  • Biopharma optimism climbs after FDA commissioner Makary's exit, survey finds
    Endpoints Signal released its Q3 Biopharma Sentiment Index, showing the highest level of industry optimism in years, according to a survey of 569 insiders. The index’s regulatory score rose sharpl…
    Endpoints · 26d agoRegulatoryPositive↗ source
  • U.S. judge denies effort to block Eli Lilly's weight-loss ad; GSK reports oncology drug approval
    A U.S. district judge rejected a request to halt Eli Lilly's advertising campaign that Novo Nordisk alleges is deceptive in promoting its weight‑loss medicines. Novo Nordisk argued the ads could m…
    STAT · 26d agoRegulatoryNeutral↗ source
  • Pennsylvania Mennonite community creates its own biotech firm after successful gene therapy in a calf with maple syrup urine disease
    A tight‑knit Mennonite community in Lancaster County, Pennsylvania, has long faced a high rate of maple syrup urine disease (MSUD), a rare genetic disorder that can be fatal. With few external biot…
    STAT · 26d agoPositive↗ source
  • Missouri AG orders Eli Lilly to stop demanding hospital data for 340B discounts
    Missouri Attorney General Catherine Hanaway sent a cease‑and‑desist letter to Eli Lilly on Oct 26, demanding the company stop requiring hospitals to submit claims data as a condition for receiving…
    STAT · 26d agoRegulatoryNegative↗ source
  • Gubra aims to expand beyond obesity drugs, targets first portfolio partner this year
    Copenhagen‑based biotech Gubra is currently known for its obesity drug candidates, but the company says its long‑term growth will depend on a broader pipeline beyond metabolism. The firm’s existin…
    Endpoints · 26d agoNeutral↗ source
  • Nonprofit revives gene therapy program after UK startup closure
    Bloomsbury Genetic Therapies, a U.K.-based gene‑therapy startup, announced it was shutting its doors after treating only a single patient. The company’s closure left its lead experimental therapy w…
    STAT · 26d agoPositive↗ source
  • Researchers isolate marine compound that may halt deadly brain-eating amoeba infections
    Brain-eating amoebas are notoriously difficult to treat and have a mortality rate that is almost 100%. The article notes that researchers have now isolated a compound from the sea that could potent…
    STAT · 26d agoPositive↗ source
  • Pediatric emergency departments remain in chronic crisis after 2022 tripledemic, says opinion piece
    The authors argue that the surge in pediatric patients that peaked in 2022 has become a routine reality, leaving emergency departments across the country in a state of permanent crisis. A rural ho…
    STAT · 26d agoNegative↗ source
  • U.S. judge rejects Novo Nordisk's bid to block Eli Lilly obesity drug ads
    A U.S. federal judge denied Novo Nordisk's request to halt television advertisements by Eli Lilly for its obesity treatments. Novo had argued the ads were misleading and sought an injunction, but…
    Endpoints · 26d agoRegulatoryNegative↗ source
  • Anthropic acquires one-person biotech Mithril Medicine to expand into life sciences
    Anthropic, known for its artificial intelligence work, announced it has purchased Mithril Medicine, a drug discovery startup run by a single individual. The deal is presented as a step in Anthropi…
    Endpoints · 26d agoDealNeutral↗ source
  • Mennonite family backs new gene-therapy startup
    A new gene‑therapy company is taking shape with financial support from members of the Amish and Mennonite communities. The story highlights the unusual partnership between a traditional religious g…
    Endpoints · 26d agoDealNeutral↗ source
  • Outpace Bio halts Phase 1 ovarian cancer CAR‑T trial
    Outpace Bio announced that it has stopped its Phase 1 trial of OPB-101, an autologous CAR‑T therapy targeting mesothelin in ovarian cancer. The company said the trial will no longer enroll patient…
    Endpoints · 26d agoNegative readoutNegative↗ source
  • RFK Jr. campaigns in Iowa as healthcare companies prepare earnings reports
    Robert F. Kennedy Jr. appeared in Iowa to support GOP gubernatorial candidate Zach Lahn, marking his final push on the campaign trail. The week’s agenda also includes earnings calls from major hea…
    STAT · 26d agoNeutral↗ source
  • STAT+: After two deaths in autoimmune cell therapy trial, Artiva is shutting down
    Recent deaths are setbacks in drug companies’ interest in applying cancer therapy strategies to autoimmune diseases.
    STAT · 26d ago↗ source
  • Roche's KRAS inhibitor divarasib shows strong results in second-line lung cancer trial at ESMO
    Roche presented data from a trial of its KRAS G12C inhibitor divarasib at the European Society for Medical Oncology meeting. The study evaluated divarasib in patients with advanced non-small cell…
    STAT · 26d agoPositive readoutPositive↗ source
  • Moderna and Merck aim to file personalized cancer vaccine for FDA approval after Phase 3 success
    Moderna CEO Stéphane Bancel said the company’s personalized cancer vaccine, intismeran, met its primary goals in a pivotal Phase 3 trial. The success was disclosed during an interview at the ESMO m…
    STAT · 27d agoPositive readoutPositive↗ source
  • Merck/Kelun ADC sac-TMT cuts death risk by one-third in advanced endometrial cancer
    A randomized Phase 3 trial showed that the antibody‑drug conjugate sacituzumab tirumotecan (sac‑TMT) reduced the risk of death by about one‑third in patients with advanced endometrial cancer. The…
    STAT · 27d agoPositive readoutPositive↗ source
  • GSK gains another cancer drug approval and unveils promising chemo data as it prepares for lung cancer approval
    GSK received regulatory approval this week for one of its cancer medicines in an additional tumor indication, expanding the portfolio that has grown since the company re-entered oncology a decade a…
    STAT · 27d agoApprovalPositive↗ source
  • Incyte reports lasting tumor responses in pancreatic cancer patients using targeted drug plus chemotherapy
    Incyte announced at the European Society for Medical Oncology meeting that its targeted therapy, when combined with standard chemotherapy, produced durable tumor responses in a subset of pancreatic…
    STAT · 27d agoPositive readoutPositive↗ source
  • Moderna CEO Bancel optimistic after Phase 3 success of mRNA melanoma vaccine intismeran
    Moderna chief executive Stéphane Bancel said the company will move quickly to obtain FDA approval for its experimental melanoma therapy intismeran after a Phase 3 trial showed positive results. Th…
    STAT · 27d agoPositive readoutPositive↗ source
  • Bon Secours Mercy Health to Acquire Surgery Partners in $5.7 B Deal, Expanding Ambulatory Surgery Network
    Nonprofit Bon Secours Mercy Health announced it will buy Surgery Partners, a publicly traded operator of more than 200 ambulatory surgery centers, short-stay hospitals and physician practices. The…
    STAT · 27d agoDealPositive↗ source
  • Employers sue UnitedHealth, alleging overpayment of workers' medical claims
    Six major U.S. companies have filed a lawsuit against UnitedHealth Group, claiming the insurer overpaid medical claims for their employees, which they say increased their costs. The plaintiffs inc…
    Endpoints · 27d agoNegative↗ source
  • WuXi AppTec lifts 2026 revenue outlook despite US defense designation dispute
    WuXi AppTec, a leading Chinese contract research and manufacturing organization, announced it has again lifted its revenue forecast for 2026. The company said the upward revision reflects accelera…
    Endpoints · 27d agoNeutral↗ source